- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01772810
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI (SCI)
September 6, 2017 updated by: Neuralstem Inc.
A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI
This is a safety study of human spinal cord-derived neural stem cell (HSSC) transplantation for the treatment of chronic spinal cord injury.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Phase I, open-label, single-site, safety study of HSSC transplantation for the treatment of chronic spinal cord injury (SCI).
Group A enrolled 4 subjects with a cord injury at T2-T12; Group B will enroll 4 subjects with a C5-C7 cord injury.
Study period will be 6 months post-operative.
Post-study, subjects will be followed for an additional 54 months.
Study Type
Interventional
Enrollment (Anticipated)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92103-8893
- Recruiting
- UCSD Medical Center, Division of Neurosurgery
-
Contact:
- Dr. Ciacci's Research Group
- Phone Number: 844-317-7836
- Email: alphastemcellclinic@ucsd.edu
-
Principal Investigator:
- Joseph Ciacci, MD
-
Sub-Investigator:
- Martin Marsala, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Lives within 500 miles of study center (For Group B)
- Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling] and comply with the study procedures
- Men and women 18-65 years old
- Women must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or who have undergone hysterectomy or oophorectomy or surgical sterilization)
- At least 1 year but no more than 2 years from time of injury at the time of surgery
- SCI injury classified as AIS-A complete as confirmed by the PI and a Physical Medicine and Rehabilitation doctor or other SCI Medicine board certified physician based on a complete ISNC SCI examination
Neurologic level of injury:
- Group A: injury within cord segments T2-T12;
- Group B: injury within cord segments C5-C7
- Confirmation of bone fusion by CT scan
- Agrees to the visit schedule as outlined in the informed consent
- All required vaccinations current at the time of enrollment: tetanus/diptheria (TDAP), herpes zoster/shingles (Zostavax®: within last 10 years and must be prior to surgery), pneumonia (Pneumovax®), seasonal/H1N1 flu vaccines (as appropriate for season). Any missing vaccination will be provided at the screening if consented by the otherwise eligible patient who will then be scheduled for surgery no less than 30 days post vaccination.
Exclusion Criteria:
- SCI due to penetrating trauma such as gun shot or stabbing wound
- SCI injuries involving complete spinal cord transection
- Etiology of paraplegia or weakness related to other or additional neurologic process
- MRI evidence of syrinx, multiple cysts, or a cyst with greater than 2cm in length or injury site involving greater than 2cm of the cord
- Current or peak Panel Reactive Antibody (PRA) due to alloantibodies > 20% receiving their first allograft or presence of antibodies against HLA of the donor cells
- Receipt of any investigational drug or device within 30 days prior to surgery
- Receipt of any cell infusion other than blood transfusion
Any concomitant medical disease or condition noted below:
- Coagulopathy with INR > 1.4 at the time of screening
- Active infection
- Active hypotension requiring vasopressor therapy
- Skin breakdown over the site of surgery
- History of Malignancy (except for non-melanoma skin cancer)
- Primary or secondary immune deficiency
- Persistent MRI artifact that would prevent imaging post-op h. Creatinine >1.5, liver function tests (SGOT/SGPT, Bilirubin, Alk Phos) > 2x upper limit of normal, hematocrit/hemoglobin < 30/10, total WBC < 3000, uncontrolled hypertension (systolic > 180 or diastolic > 100) or uncontrolled diabetes (defined as hemoglobin A1C >8), evidence of GI bleeding by hemoccult test, positive tuberculosis, hepatitis B or C, or human immunodeficiency virus (HIV)
Presence of any of the following conditions:
- Current drug abuse or alcoholism
- Unstable medical conditions
- Unstable psychiatric illness including psychosis and untreated major depression
- Any condition that the Investigator or primary physician feels may interfere with participation in the study
- Any condition that the surgeon feels may pose complications for the surgery
- Known hypersensitivity to basiliximab, tacrolimus or mycophenolate mofetil
- Inability to provide informed consent as determined by screening protocol.
- Stage III or above decubitus wound, other open wound, or active colostomy;
- Autoimmune diseases, for which chronic corticosteroids or immunosuppression therapy may be needed;
- Implanted spine stimulator;
- Uncontrolled spasticity;
- Uncontrolled neuropathic pain
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Surgical implantation of human spinal cord stem cells
Surgical implantation of human spinal cord derived neural stem cells.
|
Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events and clinically significant laboratory abnormalities
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Graft survival in the transplant site as determined by MRI (for Group A) and via autopsy, if one is completed.
Time Frame: Month 60
|
Effectiveness of immunosuppression as determined by absence of donor-specific HLA antibodies.
|
Month 60
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
EMG, SCIM, ISNC SCI, and Bowel and bladder follow-up
Time Frame: 60 months
|
60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joseph Ciacci, MD, UCSD Medical Center, Division of Neurosurgery
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 1, 2014
Primary Completion (ANTICIPATED)
July 1, 2018
Study Completion (ANTICIPATED)
December 1, 2022
Study Registration Dates
First Submitted
January 14, 2013
First Submitted That Met QC Criteria
January 18, 2013
First Posted (ESTIMATE)
January 21, 2013
Study Record Updates
Last Update Posted (ACTUAL)
September 11, 2017
Last Update Submitted That Met QC Criteria
September 6, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NS2010-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injury (SCI)
-
Kessler FoundationUnited States Department of DefenseCompleted
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSCI - Spinal Cord Injury | Incomplete Spinal Cord InjuryUnited States
-
Thomas More KempenAZ HerentalsRecruiting
-
University of MinnesotaRecruitingSCI - Spinal Cord InjuryUnited States
-
Chang Gung UniversityUnknownSpinal Cord Injury(SCI)Taiwan
-
US BionicsCompleted
-
AbbVieRecruitingSpinal Cord Injury (SCI)United States, Australia, Canada, Israel, Japan, Korea, Republic of, Spain
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)Completed
-
Kessler FoundationRecruiting
-
Jill M. Wecht, Ed.D.Icahn School of Medicine at Mount SinaiRecruitingBlood Pressure | Spinal Cord Injuries | SCI - Spinal Cord Injury | Blood Pressure Disorders | Traumatic Spinal Cord Injury | Acute Spinal Cord Injury | Neuromodulation | Spinal Cord StimulationUnited States
Clinical Trials on Human spinal cord stem cells.
-
Shenzhen Beike Bio-Technology Co., Ltd.The Second Affiliated Hospital of Kunming Medical UniversityUnknown
-
Neuralstem Inc.UnknownAmyotrophic Lateral SclerosisUnited States
-
Limin RongCompleted
-
Central South UniversityUnknown
-
Shenzhen Beike Bio-Technology Co., Ltd.Shandong Jiaotong Hospital; Association for the Handicapped Of JinanCompleted
-
Asia Cell Therapeutics (Shanghai) Co., Ltd.Not yet recruitingAcute Respiratory Distress Syndrome
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingLumbar Disc Herniation | Lumbar Disc DegenerationChina
-
Yan'an Affiliated Hospital of Kunming Medical UniversityRecruitingDiabetic Nephropathy | Mesenchymal Stem CellsChina
-
Affiliated Hospital to Academy of Military Medical...Unknown
-
Shenzhen Beike Bio-Technology Co., Ltd.The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaboratorsUnknownProgressive Multiple Sclerosis | Neuromyelitis Optica.China